Abstract
Purpose
To determine whether combinations of antifungal drugs are effective and safe for patients in intensive-care units.
Methods
This study compared the efficacy and safety of caspofungin (CAS), voriconazole (VOR), amphotericin B liposome (L-AmB), CAS+VOR, and CAS+L-AmB as empirical, preemptive, and targeted therapies for invasive fungal infection (IFI).
Results
Comparing the CAS, VOR, and CAS+VOR groups revealed that there were no differences in response rates between all therapy types, IFI-associated death within 90 days was less common in the CAS+VOR group (1.8%) than the VOR group (14.3%), and there were more adverse events in the VOR group than in the CAS group (P < 0.05). For empirical or preemptive therapy, the CAS group had a better response rate (80.0%) than the CAS+VOR group (47.1%), and there were more adverse events in the VOR group than in the CAS group (P < 0.05). For targeted therapy, no differences were found for efficacy and safety. There were no differences among the CAS, L-AmB, and CAS+L-AmB groups in efficacy and safety.
Conclusion
Patients who received CAS monotherapy as an empirical or preemptive therapy could achieve good outcomes. Patients who received CAS+VOR or CAS+L-AmB achieved almost the same outcomes when compared with those who received CAS, VOR, and L-AmB monotherapy as targeted therapies, but those who received CAS+VOR had a lower IFI mortality rate than did those who received VOR monotherapy.
Abbreviations
IFI, invasive fungal infection; ICUs, intensive-care units; IC, invasive candidiasis; IA, invasive aspergillosis; CAS, Caspofungin; VOR, Voriconazole; L-AmB, Amphotericin B liposome; CAS+VOR, CAS and VOR; CAS+L-AmB, CAS and L-AmB; IDSA, Infectious Diseases Society of America.
Data Sharing Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Ethics Approval and Informed Consent
The Second Affiliated Hospital of Xi’an Jiaotong University Research Ethics Committee approved the study protocol. The consent was waived due to the retrospective nature of the review. We keep the privacy of the participants confidential. We confirm that the data was anonymized and maintained with confidentiality, and the study compliance with the Declaration of Helsinki.
Acknowledgments
The authors sincerely acknowledge the doctors in the ICUs who helped us in this study.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Disclosure
Authors declare no conflicts of interest.